Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.32 |
| ▸ | PRPS1 | P60891 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25344077 | 0.88 | SSTR4 (0.42) | SSTR4NPSR1CPB2PRPS1CA14 | |
| SCHEMBL25342185 | 0.84 | USP30 (0.31) | — | |
| SCHEMBL30568447 | 0.84 | USP30 (0.31) | — | |
| SCHEMBL30568456 | 0.77 | PRPS1 (0.39) | SSTR4NPSR1CPB2PRPS1 | |
| SCHEMBL25343570 | 0.75 | PRPS1 (0.39) | SSTR4NPSR1CPB2PRPS1 | |
| SCHEMBL30568387 | 0.75 | PRPS1 (0.39) | SSTR4NPSR1CPB2PRPS1 | |
| SCHEMBL25343063 | 0.75 | SSTR4 (0.45) | SSTR4NPSR1CPB2PRPS1CA14 | |
| SCHEMBL30568651 | 0.75 | SSTR4 (0.45) | SSTR4NPSR1CPB2PRPS1CA14 | |
| SCHEMBL25344167 | 0.75 | PRPS1 (0.42) | SSTR4NPSR1CPB2PRPS1 | |
| SCHEMBL25344478 | 0.75 | DYRK1A (0.40) | CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4472739-A1 | IMIDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2024-12-11 | — | — | EP | disclosed |
| WO-2023148129-A1 | IMIDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-10 | — | — | WO | disclosed |